successfully inspected by US-FDA, ANVISA and Russian authorities
New publication
Losan Pharma and FabRx have demonstrated the potential of selective laser sintering 3D printing to fabricate orodispersible printlets with characteristics similar to a commercial orally disintegrating tablet, but with the added benefit of using a manufacturing technology able to prepare medicines individualized to the patient. The study was published in Pharmaceutics 2020, 12, 110.
WE MAKE APIs PERFORM
We provide solutions to challenging tasks with a view to improved API stability, superior bioavailability, customised release and increased patient compliance.
Innovation
Innovation means staying a step ahead and looking beyond what already exists.
Development
We are your one-stop solution partner from lab scale to industrial scale.
Manufacturing
We provide manufacturing services for solids, semi-solids and liquids.
Losan Pharma GmbH
As a full-service CDMO, we are able to meet our customers’ rising expectations concerning innovative product development, state-of-the-art technologies and equipment, and modern facilities.
Losan has successfully passed inspections by the U.S. FDA, ANVISA, Russian and Turkish Authorities and numerous customers to supply medicinal products to the worldwide market.
BE PART OF LOSAN PHARMA
LOSAN NEWS
- IHK-Geschäftsführer Salomon bei Losan Pharma in Eschbach
- Praxisbericht Pelletherstellung
- Großer Preis des Mittelstandes 2020
- Selective laser sintering 3D printing to fabricate orodispersible printlets
- New publication 30 June 2019
- WRF zu Gast bei Losan in Eschbach
- Losan fördert das Schülerforschungszentrum Region Freiburg
- Jurystufe – Großer Preis des Mittelstandes
- Großer Preis des Mittelstandes 2018
- Unternehmensprofil in der pharmind